Hanall Biopharma Stock Forecast for 2023 - 2025 - 2030
Updated on 05/02/2024
Hanall Biopharma Stock Forecast and Price Target
The average price target for Hanall Biopharma's stock lately set by several renowned analysts is ₩45000.00, which would result in a potential upside of approximately 24.65% if it reaches this mark by December 31, 2024. This estimation is based on a high estimate of ₩70000.00 and a low estimate of ₩39000.00. If you're considering investing in A009420 stock, it's important to look at its competitors too.
24.65% Upside
Hanall Biopharma Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Hanall Biopharma's Price has seen a drop from ₩71.09k to ₩0.00 – a 100.00% decrease. In the next year, analysts expect Fair Value to reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A128940 Stock Forecast | Hanmi Pharm. | Outperform |
18
|
₩316.50k | Buy/Sell | ₩382.71k | 31.12% |
| A008930 Stock Forecast | Hanmi Science | - |
14
|
₩42.55k | Buy/Sell | ₩0.00 | -100.00% |
| A000250 Stock Forecast | Sam Chun Dang Pharm. | - |
6
|
₩104.60k | Buy/Sell | ₩80.00k | -100.00% |
| A145020 Stock Forecast | Hugel | Buy |
16
|
₩211.50k | Buy/Sell | ₩201.75k | 3.55% |
| A019170 Stock Forecast | Shinpoong Pharmaceutical Co.,L... | - |
14
|
₩12.96k | Buy/Sell | ₩0.00 | -100.00% |
Hanall Biopharma Revenue Forecast for 2023 - 2025 - 2030
Hanall Biopharma's Revenue has increased by 52.26% In the last three years, going from ₩88.60B to ₩134.91B. According to 0 major analysts, Hanall Biopharma's Revenue will fall by 12.97% in the next year, reaching ₩117.42B. Professionals believe that By 2030, Hanall Biopharma's Revenue will fall to ₩115.94B– a 14.06% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A185750 Stock Forecast | Chong Kun Dang Pharmaceutical | Outperform |
16
|
₩104.30k | Buy/Sell | ₩124.29k | 43.82% |
| A069620 Stock Forecast | Daewoong pharmaceutical Co.,Lt... | Buy |
16
|
₩111.90k | Buy/Sell | ₩156.10k | 42.98% |
| A005250 Stock Forecast | Green Cross Holdings | - |
16
|
₩16.17k | Buy/Sell | ₩0.00 | -100.00% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A003090 Stock Forecast | Daewoong | Outperform |
14
|
₩18.82k | Buy/Sell | ₩38.00k | 32.84% |
| A003850 Stock Forecast | Boryung | Buy |
17
|
₩11.15k | Buy/Sell | ₩13.50k | 43.50% |
| A086450 Stock Forecast | DongKook Pharmaceutical | Buy |
16
|
₩16.48k | Buy/Sell | ₩20.00k | 45.63% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A001060 Stock Forecast | JW Pharmaceutical | Buy |
14
|
₩30.95k | Buy/Sell | ₩40.62k | 35.70% |
| A000640 Stock Forecast | Dong-A Socio Holdings | - |
13
|
₩110.20k | Buy/Sell | ₩0.00 | -100.00% |
| A170900 Stock Forecast | Dong-A ST | Outperform |
17
|
₩67.60k | Buy/Sell | ₩74.50k | 20.56% |
Hanall Biopharma EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Hanall Biopharma's EBITDA has decreased from ₩8.83B to ₩4.99B – a 43.48% drop. Next year, analysts are expecting EBITDA to reach ₩7.34B – an increase of 47.17%. Over the next seven years, the forecast is for EBITDA to grow by 70.39%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A058820 Stock Forecast | CMG Pharmaceutical | - |
14
|
₩2.24k | Buy/Sell | ₩0.00 | -100.00% |
| A140410 Stock Forecast | Mezzion Pharma | - |
6
|
₩36.55k | Buy/Sell | ₩0.00 | -100.00% |
| A102460 Stock Forecast | REYON Pharmaceutical | - |
15
|
₩15.75k | Buy/Sell | ₩0.00 | -100.00% |
Hanall Biopharma EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Hanall Biopharma's EBIT has decreased by 70.63%, going from ₩5.94B to ₩1.74B. For next year, analysts predict EBIT of ₩4.74B, which would mean an increase of 171.94%. Over the next seven years, experts predict that Hanall Biopharma's EBIT will grow at a rate of 361.01%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A047920 Stock Forecast | HLB Pharmaceutical | - |
4
|
₩34.10k | Buy/Sell | ₩0.00 | -100.00% |
| A003000 Stock Forecast | Bukwang Pharmaceutical | - |
10
|
₩6.36k | Buy/Sell | ₩17.66k | -100.00% |
| A249420 Stock Forecast | Ildong Pharmaceutical | Outperform |
12
|
₩15.53k | Buy/Sell | ₩23.00k | 60.98% |
Hanall Biopharma EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Hanall Biopharma's EPS has seen a drop from ₩386.00 to ₩0.00 – a 100.00% decrease. In the next year, analysts expect EPS to reach ₩0.00 – an increase of 100.00%. For the next six years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| A053030 Stock Forecast | BINEX | - |
16
|
₩14.01k | Buy/Sell | ₩18.00k | -100.00% |
| A007570 Stock Forecast | Ilyang Pharmaceutical Co.,Ltd | - |
13
|
₩14.56k | Buy/Sell | ₩0.00 | -100.00% |
| A243070 Stock Forecast | Huons | Outperform |
18
|
₩34.50k | Buy/Sell | ₩45.00k | 56.52% |
.jpg)